Cellectis Announces Promising Data for Eti-cel in the Treatment of NHL
Cellectis presented preliminary results from the Phase 1 clinical trial of its candidate product eti-cel at the Annual Congress of the American Society of Hematology in Orlando.
Promising Preliminary Results Presented
At the 67th Annual Congress of the American Society of Hematology in Orlando, Cellectis presented preliminary data from the Phase 1 clinical trial evaluating its candidate product eti-cel. According to the release, eti-cel demonstrated an overall response rate of 88% and a complete response rate of 63% in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) after at least two lines of treatment. This product is the first allogeneic dual CAR candidate targeting both CD20 and CD22 simultaneously.
Further In Vivo Data and Upcoming Cohort
Additional in vivo data suggest that the low-dose addition of interleukin-2 (IL-2) could enhance the expansion and persistence of CAR-T cells, according to the company. Recruitment for the cohort incorporating IL-2 will begin in the first quarter of 2026, with a comprehensive presentation of Phase 1 data scheduled for the same year.
Ongoing Research and Development Efforts
Cellectis, based in Paris and listed on Euronext Growth as well as on the Nasdaq, utilizes its genome editing platform to develop cellular and gene therapies, including eti-cel. The group continues its research in the face of challenges posed by the treatment of refractory NHL, integrating new approaches to optimize clinical outcomes.
